Shire sells some non-core medicines to Almirall

HAMPSHIRE, ENGLAND Shire Pharmaceuticals has sold some of its medicines to Almirall for $213 million.

The products include the skin treatment drugs Solaraze and Vaniqa and other medicines that the company said were not in its core therapeutic areas. Now, Shire will focus on treatments for attention deficit disorder, gastrointestinal diseases and human genetic therapies.

Chief executive Matthew Emmens said that, “Our emphasis in the international markets is on developing competitive positions for our global products that meet the needs of specialist physicians and their patients.”